Strata Critical Medical (SRTA) Revenue (2020 - 2026)

Strata Critical Medical has disclosed Revenue across 7 years of filings, most recently posting $67.4 million for Q1 2026.

• In Q1 2026, Revenue rose 87.45% year-over-year to $67.4 million; the TTM figure through Mar 2026 stood at $254.3 million (up 44.19% YoY), while the FY2025 annual figure was $197.1 million, up 34.28% from the prior year.
• Revenue improved to $67.4 million in Q1 2026, from $66.8 million in the prior quarter.
• Over the last five years, Revenue for SRTA reached as high as $71.4 million in Q3 2023 and fell as low as $26.6 million in Q1 2022.
• The 5-year median for Revenue is $49.3 million (2025), against an average of $51.3 million.
• Annual changes were most pronounced in 2022 — Revenue soared 187.18% — and 2024, when it plunged 49.52%.
• A 5-year view of Revenue shows it stood at $35.6 million in 2022, then surged by 33.24% to $47.5 million in 2023, then slipped by 23.36% to $36.4 million in 2024, then soared by 83.54% to $66.8 million in 2025, then climbed by 0.89% to $67.4 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $67.4 million, $66.8 million, and $49.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.